Royalty Pharma Plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (February 2025)

7 slides from Royalty Pharma's investor presentation, February 2025

  1. Slide 1: Royalty Pharma

    ROYALTY PHARMA

  2. Slide 2: R&D funding for litifilimab

    R&D funding for litifilimab February 2025

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or

  4. Slide 4: Biogen's litifilimab a potential first-in-class medicine for lupus

    Biogen’s litifilimab a potential first-in-class medicine for lupus 1 2 3 Biogen’s litifilimab in Phase Impressive proof-of-concept Blockbuster commercial 3 development for lupus results and favorable safety opportunity Biogen’s litifilimab (anti-BDCA2) – a novel MoA Phase 2 results published in New

  5. Slide 5: R&D funding partnership supports litifilimab development

    R&D funding partnership supports litifilimab development • R&D funding partnership with Biogen on litifilimab Mid-single digit royalty +  Up to $250m R&D funding paid over 6 quarters milestones on litifilimab  Entitled to mid-single digit royalty on worldwide sales and regulatory based milestone p

  6. Slide 6: Phase 2 results demonstrate impressive proof-of-concept

    Phase 2 results demonstrate impressive proof-of-concept Litifilimab Phase 2 CLE Study(1) Litifilimab Phase 2 SLE Study(2) (CLASI-70; proportion of patients with response) (SRI-4; proportion of patients with response) • Results demonstrated strong proof-of-concept in CLE and SLE and a favorable safet

  7. Slide 7: Litifilimab – a potential attractive new treatment option for lupus

    Litifilimab – a potential attractive new treatment option for lupus Market dynamics in SLE and CLE RP forecasts blockbuster potential for litifilimab ~600,000 ~18 months Strong marketer Unmet need Total U.S. patients, the majority of Median duration of therapy for Biogen a strong marketer in Few app

Royalty Pharma — Investor Presentation (February 2025) on 6ix